Randomized trial · people

MK-677 raised IGF-1 but not most function after hip fracture

Checked against the paper Randomized trialPublished by PepVault

The takeaway

In elderly patients after hip fracture, MK-677 raised IGF-1 without improving most measures of function, and a heart failure safety signal ended the trial early.

Kind
Randomized trial
Studied in
People
Number studied
123
Published
2011
Journal
Arch Gerontol Geriatr

What they tested

Could MK-677 (ibutamoren) help elderly patients regain physical function after a hip fracture, and would it raise their blood IGF-1 levels?

How the study was done

A randomized, double-blind, placebo-controlled phase IIb trial at several centers in 123 elderly hip fracture patients. They took 25mg/day of MK-677 (62 patients) or a placebo, a dummy treatment (61 patients), with results reported at 24 weeks.

A woman in glasses at a kitchen table with a laptop, a mug and her phone

PepVault for iPhone

Taking MK-677? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

What they found

Blood IGF-1 (insulin-like growth factor-1) rose by 51.4 ng/ml more in the MK-677 group than with placebo (p < 0.001). At 24 weeks, gait speed improved, with a 0.7-score difference in the means (p = 0.011). Stair climbing power rose by 12.5 W versus placebo, but this was not statistically clear (p = 0.292), and several other function tests showed no gain. The MK-677 group had fewer falls and fewer patients who fell at all (p = 0.096, not statistically clear), and the trial was stopped early because a limited number of patients developed congestive heart failure.

What it doesn’t show

The trial was stopped early and tested only one dose, in elderly people recovering from hip fracture. It does not show how MK-677 acts in younger or healthy people.

The paper

Adunsky et al. MK-0677 (ibutamoren mesylate) for the treatment of patients recovering from hip fracture: a multicenter, randomized, placebo-controlled phase IIb study. Arch Gerontol Geriatr. 2011.

The compound

More studies on MK-677

Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.

Track it in the app

PepVault for iPhone

Taking MK-677? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo